Provider: View Press Release
Type: Link
Title: GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19 | GSK
Description: 600,000 additional doses to be supplied to the US Government for distribution in Q1 2022
Provider: View Press Release
Type: Link
Title: ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention | GSK
Description: ViiV Healthcare announces US FDA approval of Apretude
Provider: View Press Release
Type: Link
Title: GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company | GSK
Description: GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company
Provider: View Press Release
Type: Link
Title: Xevudy (sotrovimab) granted marketing authorisation by the European Commission for the early treatment of COVID-19 | GSK
Description: GSK and Vir are committed to the ongoing evaluation of sotrovimab as the COVID-19 landscape continues to evolve
Provider: View Press Release
Type: Link
Title: GSK and Sanofi announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of phase III trial per independent Monitoring Board recommendation | GSK
Description: Companies intend to file booster data with regulatory authorities following the phase III results
Provider: View Press Release
Type: Link
Title: New data presented at ASH 2021 highlight potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in earlier lines of multiple myeloma treatment | GSK
Description: GSK announced new data from the DREAMM-9 phase I trial and two GSK collaborative studies investigating the potential use of Blenrep.